2022 World Conference on Lung Cancer (ePosters)-EP08.01-106. PD-1/PD-L1 Inhibitors Increase Myocardial Infarction in Osimertinib-Treated Patients with Non-Small Cell Lung Cancer

EP08.01-106. PD-1/PD-L1 Inhibitors Increase Myocardial Infarction in Osimertinib-Treated Patients with Non-Small Cell Lung Cancer

Back to course

Pdf Summary

A study was conducted to determine whether PD-1/PD-L1 inhibitors increase the incidence of cardiac disorders in patients being treated with osimertinib for non-small cell lung cancer (NSCLC). The study analyzed data from 11,993 participants with NSCLC in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.<br /><br />The results showed that of the 11,893 patients treated without PD-1/PD-L1 inhibitors, 5.9% developed cardiac disorders. Of the 100 patients treated with both EGFR-TKI and PD-1/PD-L1 inhibitors, 7% developed cardiac disorders. However, the odds ratio of EGFR-TKI-associated cardiac disorders in cases with and without PD-1/PD-L1 inhibitors treatment was not statistically significant.<br /><br />Furthermore, the study also analyzed the impact of PD-1/PD-L1 inhibitors on myocardial infarction. Of the 11,893 patients treated without PD-1/PD-L1 inhibitors, 0.5% developed myocardial infarction. Of the 100 patients treated with both EGFR-TKI and PD-1/PD-L1 inhibitors, 2% developed myocardial infarction. The odds ratio of EGFR-TKI-associated myocardial infarction in cases with and without PD-1/PD-L1 inhibitors treatment was statistically significant.<br /><br />In conclusion, the study found that PD-1/PD-L1 inhibitors did not increase osimertinib-associated cardiac disorders, but they did increase the incidence of osimertinib-associated myocardial infarction in NSCLC patients. However, due to the small number size of myocardial infarction cases in this study, further confirmation is needed. It is important to consider the possibility of an increased risk of myocardial infarction when administering PD-1/PD-L1 inhibitors to patients with a history of or current use of osimertinib.

Asset Subtitle

Lucheng Zhu

Meta Tag

Speaker Lucheng Zhu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

PD-1/PD-L1 inhibitors

cardiac disorders

osimertinib

non-small cell lung cancer

NSCLC

EGFR-TKI

myocardial infarction

incidence

adverse event

confirmation